title: Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
abstract: Somatostatin analogs are the first-line medical therapy for acromegaly, and the treatment of this disease has been simplified by the development of extended-release formulations of these analogs. Lanreotide is a somatostatin analog that is available either as the microparticle formulation, requiring 7- to 14-day dosing, or as the aqueous Autogel formulation, requiring 28-day dosing. This study investigated the pharmacokinetics and pharmacodynamics of lanreotide. Patients with acromegaly were given 5 injections of lanreotide microparticles, 30 mg, followed by 3 injections of lanreotide Autogel, at doses of 60, 90, or 120 mg every 28 days. The study was extended to a further 12 injections of lanreotide Autogel with dose titration. A total of 144 patients were recruited; 130 received 3 injections of lanreotide Autogel, and 130 completed the extension phase. Average minimum lanreotide concentrations (Cmin) at steady state were 1.949 +/- 0.619, 2.685 +/- 0.783, and 3.575 +/- 1.271 ng/mL for 60, 90, and 120 mg of lanreotide Autogel, respectively, showing a dose-proportional increase. Population pharmacodynamic analysis showed that the relationship between either formulation of lanreotide and serum growth hormone (GH) concentrations was best described using an inhibitory maximum response (Emax) model that allowed for the possibility of an incomplete inhibition of GH. Lanreotide elicited a maximum reduction in GH of 82%. Because patients were already being treated, baseline GH (E0) was estimated, and the value of 8.63 ng/mL was in agreement with the inclusion criteria of GH 10 ng/mL or less. The effectiveness of treatment was demonstrated by the median serum concentration of lanreotide, 1.13 ng/mL, required to lower GH to 2.5 ng/mL or less. The serum concentration that elicited half of the Emax (EC50) was estimated as 0.206 ng/mL, showing a high sensitivity to lanreotide, with a predictably high interpatient variability of 200.75% reflecting the range of dosing regimens needed to control GH.
authors.affiliation: Pharmacokinetics and Metabolism Service, Ipsen Pharma S.A., 08980-Saint Feliu Llobregat, Barcelona, Spain.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Cendros
authors.forename: Concepción
authors.initials: C
authors.lastname: Peraire
authors.forename: Iñaki Fernández
authors.initials: IF
authors.lastname: Trocóniz
authors.forename: Rossend
authors.initials: R
authors.lastname: Obach
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D005260:Female; D005782:Gels; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008954:Models, Biological; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D005782:Gels; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin